TY - JOUR
T1 - Thrombin activation of proteinase-activated receptor 1 potentiates the myofilament Ca 2+ sensitivity and induces vasoconstriction in porcine pulmonary arteries
AU - Maki, Jun
AU - Hirano, Mayumi
AU - Hoka, Sumio
AU - Kanaide, Hideo
AU - Hirano, Katsuya
PY - 2010/2
Y1 - 2010/2
N2 - Background and purpose: Thrombus formation is commonly associated with pulmonary arterial hypertension (PAH). Thrombin may thus play an important role in the pathogenesis and pathophysiology of PAH. Hence, we investigated the contractile effects of thrombin and its mechanism in pulmonary artery. Experimental approach: The cytosolic Ca 2+ concentrations (Ca 2+ i), 20 kDa myosin light chain (MLC20) phosphorylation and tension development were evaluated using the isolated porcine pulmonary artery. Key results: Thrombin induced a sustained contraction in endothelium-denuded strips obtained from different sites of a pulmonary artery, ranging from the main pulmonary artery to the intrapulmonary artery. In the presence of endothelium, thrombin induced a transient relaxation. The contractile effect of thrombin was abolished by either a protease inhibitor or a proteinase-activated receptor 1 (PAR 1) antagonist, while it was mimicked by PAR 1-activating peptide (PAR 1AP), but not PAR 4AP. The thrombin-induced contraction was associated with a small elevation of Ca 2+ i and an increase in MLC20 phosphorylation. Thrombin and PAR 1AP induced a greater increase in tension for a given Ca 2+ i elevation than that obtained with high K +-depolarization. They also induced a contraction at a fixed Ca 2+ concentration in -toxin-permeabilized preparations. Conclusions and implications: The present study revealed a unique property of the pulmonary artery. In contrast to normal arteries of the systemic circulation, thrombin induces a sustained contraction in the normal pulmonary artery, by activating PAR 1 and thereby increasing the sensitivity of the myofilament to Ca 2+. This responsiveness of the pulmonary artery to thrombin may therefore contribute to the pathogenesis and pathophysiology of PAH.
AB - Background and purpose: Thrombus formation is commonly associated with pulmonary arterial hypertension (PAH). Thrombin may thus play an important role in the pathogenesis and pathophysiology of PAH. Hence, we investigated the contractile effects of thrombin and its mechanism in pulmonary artery. Experimental approach: The cytosolic Ca 2+ concentrations (Ca 2+ i), 20 kDa myosin light chain (MLC20) phosphorylation and tension development were evaluated using the isolated porcine pulmonary artery. Key results: Thrombin induced a sustained contraction in endothelium-denuded strips obtained from different sites of a pulmonary artery, ranging from the main pulmonary artery to the intrapulmonary artery. In the presence of endothelium, thrombin induced a transient relaxation. The contractile effect of thrombin was abolished by either a protease inhibitor or a proteinase-activated receptor 1 (PAR 1) antagonist, while it was mimicked by PAR 1-activating peptide (PAR 1AP), but not PAR 4AP. The thrombin-induced contraction was associated with a small elevation of Ca 2+ i and an increase in MLC20 phosphorylation. Thrombin and PAR 1AP induced a greater increase in tension for a given Ca 2+ i elevation than that obtained with high K +-depolarization. They also induced a contraction at a fixed Ca 2+ concentration in -toxin-permeabilized preparations. Conclusions and implications: The present study revealed a unique property of the pulmonary artery. In contrast to normal arteries of the systemic circulation, thrombin induces a sustained contraction in the normal pulmonary artery, by activating PAR 1 and thereby increasing the sensitivity of the myofilament to Ca 2+. This responsiveness of the pulmonary artery to thrombin may therefore contribute to the pathogenesis and pathophysiology of PAH.
UR - http://www.scopus.com/inward/record.url?scp=77249091781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77249091781&partnerID=8YFLogxK
U2 - 10.1111/j.1476-5381.2009.00591.x
DO - 10.1111/j.1476-5381.2009.00591.x
M3 - Article
C2 - 20128804
AN - SCOPUS:77249091781
SN - 0007-1188
VL - 159
SP - 919
EP - 927
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 4
ER -